Compare HHH & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HHH | NAMS |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.1B |
| IPO Year | 2023 | N/A |
| Metric | HHH | NAMS |
|---|---|---|
| Price | $72.05 | $35.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $90.00 | $46.75 |
| AVG Volume (30 Days) | 414.0K | ★ 1.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $1,474,892,000.00 | N/A |
| Revenue This Year | $14.04 | $17.96 |
| Revenue Next Year | N/A | $540.65 |
| P/E Ratio | $515.07 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $61.01 | $20.53 |
| 52 Week High | $91.07 | $42.21 |
| Indicator | HHH | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 57.72 |
| Support Level | $61.79 | $33.83 |
| Resistance Level | $86.24 | $37.27 |
| Average True Range (ATR) | 1.60 | 1.74 |
| MACD | 0.04 | 0.42 |
| Stochastic Oscillator | 63.22 | 71.19 |
Howard Hughes Holdings Inc, through its subsidiary, operates a large-scale, mixed-use real estate platform focused on the development of master planned communities (MPCs), the investment in strategic real estate development opportunities, and the ownership and operation of income-producing properties. The group operates through three reportable business segments: Operating Assets, MPCs, and Strategic Developments. Maximum revenue is generated from the MPC segment, which consists of the development and sale of land in large-scale, long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. Revenues are mainly generated through the sale of residential and commercial land to homebuilders and developers.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.